Investor Relations

Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology and neurology. Revance’s science is based upon a proprietary TransMTS® peptide technology, which, when combined with active drug molecules, may help address current unmet needs.

Revance’s initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The company’s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform.

+ 1.50 (+6.11%)
4:00 PM ET on Nov 22, 2017
Delayed at least 20 minutes.

Jeanie D. Herbert
Sr. Director, Investor Relations

Burns McClellan
Ami Bavishi

Revance Therapeutics, Inc.
P.O. Box 303
Newark, California 94560-0303
Phone: (510) 742-3400
Fax: (510) 742-3401

Transfer Agent
+1 (877) 373 6374
(US, Canada, Puerto Rico)
+1 (781) 575 3120 (non-US)

Shareholder Correspondence should be mailed to:
P.O. Box 505000
Louisville, KY  40233
Shareholder Overnight correspondence should be sent to:
462 South 4th Street, Suite 1600
Louisville, KY 40202

Press Releases

Events & Webcasts

Presentations and Corporate Materials

Investor Relations
Date Document Type
Nov 15, 2017 Fact Sheet
Nov 13, 2017 Investor Presentation
May 18, 2017 Phase 2 Cervical Dystonia 24-Week Results Presentation
= add file to Briefcase
Shareholder Tools